Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.5 mg/kg Clear all
Recruiting Phase 1 Interventional

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

NCT03721068
View directory record Official record
Conditions
Neuroblastoma, Osteosarcoma
Interventions
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Months and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2044
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 28, 2026, 6:09 PM EDT
Recruiting Phase 3 Interventional

Cardiac Sarcoidosis Randomized Trial

NCT03593759
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis
Interventions
Prednisone or Prednisolone, Methotrexate
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

NCT00661141
View directory record Official record
Conditions
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Interventions
Antizol, Placebo, Ethanol
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 28, 2026, 6:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

Ultrasound Guided Serratus Anterior Plane Block for Rib Fractures

NCT05748366
View directory record Official record
Conditions
Rib Fracture Multiple
Interventions
Serratus Anterior Plane Block (SAPB), Standard Analgesic Medications
Procedure · Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 28, 2026, 6:09 PM EDT
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries

NCT05444751
View directory record Official record
Conditions
Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Radiculopathy
Interventions
General anesthetic, SA + ESP
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Withdrawn Phase 4 Interventional

Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population

NCT04464512
View directory record Official record
Conditions
Addiction Opiate, Chronic Pain, Fractures, Bone, Buprenorphine Dependence
Interventions
Sufentanil
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)

NCT00973102
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Premarin IV, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional Results available

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

NCT00415857
View directory record Official record
Conditions
Leukemia
Interventions
Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Results available

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT02222688
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
cirmtuzumab
Drug
Lead sponsor
Thomas Kipps
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

NCT03137173
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
ceftobiprole medocaril, vancomycin+aztreonam
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 4 Interventional

Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty

NCT04828083
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Total Knee Arthroplasty
Interventions
Lidocaine IV, Saline IV
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

NCT03136185
View directory record Official record
Conditions
Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
Interventions
Bomedemstat
Drug
Lead sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 28, 2026, 6:09 PM EDT
Recruiting Early Phase 1 Interventional

Ketamine in Severe Traumatic Brain Injury

NCT06062628
View directory record Official record
Conditions
Traumatic Brain Injury, Traumatic Encephalopathy
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

NCT03065335
View directory record Official record
Conditions
Healthy Volunteer, Major Depressive Disorder, Depression
Interventions
Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
Drug · Other · Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study

NCT01997515
View directory record Official record
Conditions
Pain, Obesity, Hypoxia
Interventions
Ketamine, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 28, 2026, 6:09 PM EDT
Withdrawn Phase 1 Interventional

Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study

NCT00676559
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Efalizumab, Ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction

NCT00540982
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
indocyanine green, lidocaine, vinorelbine ditartrate, high performance liquid chromatography, intracellular fluorescence polarization analysis, liquid chromatography, mass spectrometry, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 28, 2026, 6:09 PM EDT
Terminated Not applicable Interventional Results available

Intravenous Versus Inhalational Anesthesia in Parkinson's Disease

NCT00615472
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Isoflurane, Remifentanil, Propofol
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02558140
View directory record Official record
Conditions
Neoplasms
Interventions
RO6874813
Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

NCT00575055
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
186
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 28, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

NCT00585182
View directory record Official record
Conditions
Obesity, Venous Thrombosis, Anticoagulants
Interventions
Enoxaparin 0.5 mg/kg once daily
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 28, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

Ketamine for Veterans With Parkinson's Disease

NCT06231563
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ketamine, Remimazolam
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 6:09 PM EDT